A new, long-term study examined the antibody response to natural infection with adeno-associated virus (AAV) in chimpanzees for the purpose of characterizing the broad-based immune responses that could reduce the effectiveness of AAV vector-based gene delivery strategies. The study, which demonstrated the production of antibodies able to cross-neutralize multiple AAV serotypes, is published in Human Gene Therapy Clinical Development.
↧